News8 months ago
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
LAVA Therapeutics N.V. LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million...